CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
OPERATING EXPENSES
General and administrative	$ 472	$ 452
Research and development	350	630
Total operating expenses	822	1,082
Interest and other expenses (income), net	56	(60)
Loss from operations before taxes	878	1,022
Income tax benefit	(162)	0
NET LOSS	716	1,022
Less: Net Loss attributable to the noncontrolling interest	0	0
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 716	$ 1,022
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutic Corp. stockholders (in dollars per share)	$ 0.02	$ 0.02
Basic and diluted shares outstanding (in shares)	40,885	40,885